Protocol No.: MK1084-012

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)
Principal Investigator
Daboul, Nour
Phase
III
Age Group
Adult
Applicable Disease Site
Gastrointestinal Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Meg Zafiris
Research Specialist

View on ClinicalTrials.gov